Skip to content

Dexmedetomidine exerts protective effects on liver transplantation form experimental study to clinical evaluation

Dexmedetomidine exerts protective effects on liver transplantation form experimental study to clinical evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400088867
Enrollment
Unknown
Registered
2024-08-28
Start date
2024-07-18
Completion date
Unknown
Last updated
2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver transplant

Interventions

Dexmedetomidine group:NA

Sponsors

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: First, patients with end-stage liver disease due to various liver diseases were included, and the surgical methods were allogeneic orthotopic liver transplantation, aged between 16 and 65 years.

Exclusion criteria

Exclusion criteria: Patients with combined multi-organ transplantation, incomplete clinical records, and lost contact with follow-up were excluded.

Design outcomes

Primary

MeasureTime frame
survival rate;

Secondary

MeasureTime frame
Liver function;

Countries

China

Contacts

Public ContactSheng Wang

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

iamsheng2020@ustc.edu.cn+86 191 5600 7726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026